Mechanism of the Pharmacokinetic Interaction between Methotrexate and Benzimidazoles

Pauline Breedveld, Jan H.M. Schellens(Utrecht University), Olaf van Tellingen(Dutch Cancer Society), Alfred H. Schinkel(Oncode Institute), Noam Zelcer(Amsterdam Neuroscience), Piet Borst(The Netherlands Cancer Institute), Jos H. Beijnen(The Netherlands Cancer Institute), Özgür Sönmezer, Matthijs M. Tibben(Slotervaartziekenhuis), Dick Pluim
Cancer Research
August 15, 2004
10.1158/0008-5472.can-03-4062
Cited by 233

Related Papers

Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs
|Cell|1994|2.3k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k
Overcoming the blood–brain tumor barrier for effective glioblastoma treatment
|Drug Resistance Updates|2015|1k
Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins
|Proceedings of the National Academy of Sciences|1997|941
Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine
|Proceedings of the National Academy of Sciences|1997|884